Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2010. The report serves as a notification to the market regarding the company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a corporate governance notification regarding share capital and voting rights.
Material Changes
The filing does not report material changes in financial performance or operations compared to prior periods. It solely discloses the status of issued share capital as of April 30, 2010.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, risk factors, or contingencies. It is a statutory disclosure of share counts intended to assist shareholders in calculating notification thresholds under Financial Services Authority rules.
Important Facts for Investors
- Issued Share Capital: As of April 30, 2010, the company had 5,666,683,746 Ordinary shares of 25p each.
- Treasury Shares: 474,194,158 Ordinary shares are held in Treasury.
- Total Voting Rights: The total number of voting rights is 5,192,489,588.
- Reporting Date: The notification was signed and dated May 4, 2010.